Nucleotide substitutions in the p53 promoter at 4 mutated positions, including position -250, and in the p16INK4a promoter at positions -735, -493, and -191 are found not only in Taiwanese patients with uterine leiomyoma (Hsieh et al., 2007) and frequently in melanoma families from other populations (Harland et al., 2000) but also in control groups; p53 promoter polymorphism at position -250 and p16INK4a promoter polymorphism at position -191 are located within CpG dinucleotides. Here, CDKN2A is linked to Uterine leiomyoma.